These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs? Clarke CE Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811 [TBL] [Abstract][Full Text] [Related]
7. Neuroprotection by dopamine agonists. Lange KW; Rausch WD; Gsell W; Naumann M; Oestreicher E; Riederer P J Neural Transm Suppl; 1994; 43():183-201. PubMed ID: 7884400 [TBL] [Abstract][Full Text] [Related]
8. Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. Storch A; Wolz M; Beuthien-Baumann B; Löhle M; Herting B; Schwanebeck U; Oehme L; van den Hoff J; Perick M; Grählert X; Kotzerke J; Reichmann H Neurology; 2013 May; 80(19):1754-61. PubMed ID: 23576623 [TBL] [Abstract][Full Text] [Related]
9. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Iida M; Miyazaki I; Tanaka K; Kabuto H; Iwata-Ichikawa E; Ogawa N Brain Res; 1999 Aug; 838(1-2):51-9. PubMed ID: 10446316 [TBL] [Abstract][Full Text] [Related]
10. Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry. Depboylu C; Maurer L; Matusch A; Hermanns G; Windolph A; Béhé M; Oertel WH; Höglinger GU Neuroimage; 2013 Oct; 79():191-200. PubMed ID: 23631981 [TBL] [Abstract][Full Text] [Related]
15. Dopamine agonists and neuroprotection in Parkinson's disease. Olanow CW; Jenner P; Brooks D Ann Neurol; 1998 Sep; 44(3 Suppl 1):S167-74. PubMed ID: 9749590 [TBL] [Abstract][Full Text] [Related]
16. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Bonuccelli U; Del Dotto P; Rascol O Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557 [TBL] [Abstract][Full Text] [Related]
17. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296 [TBL] [Abstract][Full Text] [Related]
18. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Albrecht S; Buerger E Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998 [TBL] [Abstract][Full Text] [Related]
19. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. de la Fuente-Fernández R; Schulzer M; Mak E; Sossi V Parkinsonism Relat Disord; 2010 Jul; 16(6):365-9. PubMed ID: 20471298 [TBL] [Abstract][Full Text] [Related]
20. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. Ling ZD; Robie HC; Tong CW; Carvey PM J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]